Episode 54
Biotech Hangout
00:00
CMS and the Value Proposition of Drugs
I struggle with the aversion to this negotiation process and assuming that CMS enters these negotiations in good faith. Should companies really be scared of having to articulate the value proposition of their drugs? So my hope is that as we go through a few rounds of these, the industry will recognize that it's not inappropriate for a large payer to expect appropriate value for the drug. I think you're spot on. These decisions aren't, the decision making process hasn't changed yet. We're still looking for great drugs.
Transcript
Play full episode
